NIH Issues Permanent Gain-of-Function Ban as Study Warns Unilateral Oversight Has Structural Limits

The National Institutes of Health released a formal government-wide policy notice on July 28 establishing what it called an explicit prohibition on dangerous gain-of-function research, moving beyond the interim suspensions that had been in place since mid-2025. The primary document, NIH notice NOT-OD-26-101, describes the action as implementing Section 4 of Executive Order 14292, which the Trump administration signed in May 2025.

According to a statement reviewed on the NIH Director's page, Director Jay Bhattacharya framed the policy as fulfilling a confirmation-hearing pledge to provide "strong and transparent oversight" of NIH-supported research. The notice itself says all research activities previously identified as potential dangerous gain-of-function research under earlier notices remain paused until NIH-specific implementation requirements are finalized, and that NIH will not accept new competitive applications for such work.

The scope matters for reading the actual risk picture. Under notice NOT-OD-25-127, issued in June 2025, NIH had already moved to terminate funding for dangerous gain-of-function work conducted by foreign entities in countries of concern, and to suspend all other such projects pending the new policy. The July 28 notice formalizes what those interim steps pointed toward: a standing prohibition rather than a temporary pause.

What the policy doesn't resolve is the structural problem that sits directly underneath it. A sole-author study by Professor Seokbeom Kwon of KAIST, published in Science on June 5, 2026, analyzed roughly 600,000 research papers and found that single-country security oversight of dual-use research carries fundamental limits in global efficacy. According to an announcement from KAIST reviewed via EurekAlert, Kwon found that tightening controls domestically can impose disproportionate costs on the country doing the tightening, while research with equivalent security-sensitive potential continues abroad.

That's not an argument against oversight. It's a description of what oversight can and can't do when applied by one government to a globally distributed scientific enterprise. The dual-use ambiguity here is real and shouldn't be papered over: gain-of-function research on pathogens can inform vaccine design, improve diagnostics, and help model pandemic trajectories. It can also, as the biosecurity debate has long acknowledged, generate materials and knowledge that raise serious proliferation concerns if access controls fail or if lab biosafety breaks down.

The KAIST analysis appears in the same policy environment that produced NOT-OD-26-101. As noted in the EurekAlert release, Executive Order 14292 had already intensified federal scrutiny over biological research with security implications. Kwon's paper, titled "Dual-use research under scrutiny," provides what EurekAlert called the first large-scale empirical basis for that policy discussion, one that the U.S. government's new notice doesn't directly engage.

The timing of Tuesday's NIH announcement is worth noting as a distinct artifact. Bloomberg Law reported July 28 that NIH outlined its strategy to end gain-of-function research the day before former public health official Anthony Fauci was scheduled to appear before the Senate, a sequencing that reflects political as much as scientific logic. That context doesn't change what the policy actually says, but it's relevant to how confident one should be that the underlying oversight architecture is being designed around empirical risk rather than political symbolism.

The more durable policy question, at moderate confidence, is whether a government-wide prohibition administered through NIH grant conditions can actually close the hazard gap, or whether it shifts work to jurisdictions with less oversight and no termination authority. The KAIST data suggests that gap is structural, not incidental. The new notice doesn't answer that.

Sources cited:
- NIH Notice NOT-OD-26-101 (grants.nih.gov) (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-26-101.html)
- NIH Director Statement, July 28, 2026 (nih.gov) (https://www.nih.gov/about-nih/nih-director/statements/announcement-release-us-government-policy-stopping-high-risk-life-sciences-research)
- Bloomberg Law, July 28, 2026 (https://news.bloomberglaw.com/health-law-and-business/trumps-nih-ends-funding-support-for-gain-of-function-research)
- NIH Notice NOT-OD-25-127 (grants.nih.gov) (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-25-127.html)
- EurekAlert / KAIST press release, June 4, 2026 (https://www.eurekalert.org/news-releases/1131017)